In summary, recent understanding of the effects of the synergistic inhibition of short-acting anti-angiogenic agents and SDRT on tumor endothelium provides new targets for improving local cure of human cancer with radiation. The conclusion from this study, that a single dose of Pazopanib substantially sensitizes tumors to the effects SDRT, indicates this as a highly promising treatment strategy for sarcomas resistant to conventional RT and chemotherapy.